Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated
Your view on PRLD
Overview
What the company does, where it operates, and who runs it.
About Prelude Therapeutics Incorporated
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Krishna Vaddi
- Headquarters
- 200 Powder Mill Road, Wilmington, DE, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Krishna Vaddi
- Headquarters
- 200 Powder Mill Road, Wilmington, DE, US
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme.
The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors.
The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Prelude Therapeutics Incorporated, and the rating behind it. PRLD last traded at $4.59; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Prelude Therapeutics Incorporated. Starting points for Prelude Therapeutics Incorporated: EPS -$0.61, beta 0.96 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Prelude Therapeutics Incorporated. Prelude Therapeutics Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Prelude Therapeutics Incorporated. Trailing twelve-month EPS for Prelude Therapeutics Incorporated stands at -$0.61. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Prelude Therapeutics Incorporated. Prelude Therapeutics Incorporated has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Prelude Therapeutics Incorporated valued side by side against its closest peers. Prelude Therapeutics Incorporated is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Prelude Therapeutics Incorporated, and how their positions are changing. At a $261.3M market value, institutional positions materially move Prelude Therapeutics Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Prelude Therapeutics Incorporated executives and directors. Shares of Prelude Therapeutics Incorporated have traded between $0.61 and $4.22 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Prelude Therapeutics Incorporated. Prelude Therapeutics Incorporated is a $261.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Prelude Therapeutics Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Prelude Therapeutics Incorporated. Coverage tracks Prelude Therapeutics Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.